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Empirical evidences suggest that both common and rare variants contribute to complex disease etiology. Although the effects of
common variants have been thoroughly assessed in recent genome-wide association studies (GWAS), our knowledge of the impact of
rare variants on complex diseases remains limited. A number of methods have been proposed to test for rare variant association in
sequencing-based studies, a study design that is becoming popular but is still not economically feasible. On the contrary, few (if any)
methods exist to detect rare variants in GWAS data, the data we have collected on thousands of individuals. Here we propose two
methods, a weighted haplotype-based approach and an imputation-based approach, to test for the effect of rare variants with GWAS
data. Both methods can incorporate external sequencing data when available. We evaluated our methods and compared them with
methods proposed in the sequencing setting through extensive simulations. Our methods clearly show enhanced statistical power
over existing methods for a wide range of population-attributable risk, percentage of disease-contributing rare variants, and proportion
of rare alleles working in different directions. We also applied our methods to the IFIH1 region for the type 1 diabetes GWAS data
collected by theWellcome Trust Case-Control Consortium. Ourmethods yield p values in the order of 103, whereas themost significant
p value from the existing methods is greater than 0.17. We thus demonstrate that the evaluation of rare variants with GWAS data is
possible, particularly when public sequencing data are incorporated.Recent studies suggest that rare variants play an important
role in the etiology of complex traits,1,2 revealing that rare
variants generally have larger genetic effects than common
variants.3–6 There is also evidence that multiple rare vari-
ants together influence the risk of complex diseases,
making it sensible to combine information across them.
Although there is a lingering debate over the two schools
of hypothesis for the genetics underlying complex traits,
namely common disease common variants and common
disease rare variants, the community has now gradually
reached a consensus that both common and rare variants
contribute to the underlying genetic mechanism.7
However, unlike common variants, whose impact on
human diseases has been thoroughly evaluated in the
recent wave of genome-wide association studies (GWAS),
rare variants are largely waiting for the evaluation of their
impact. Rare variants are attracting increasing attention
from researchers for two major reasons. First, common
variants identified through GWAS only explain a small
proportion of the overall heritability, and rare variants
hold the promise to explain some of the missing herita-
bility.8–10 Second, massively parallel sequencing technolo-
gies have made it feasible to search after rare variants.2,11
In preparation for the coming wave of sequencing-based
studies, a number of methods have been proposed to test
for the effect of rare variants in aggregate.12–18 However,
whole-genome sequencing is still cost prohibitive, and
only a few groups can afford to sequence a relatively small
number of samples, limiting the statistical power to detect
association. On the other hand, little, if any, attention has
been given to GWAS data for the evaluation of rare vari-1Department of Genetics, University of North Carolina at Chapel Hill, Chap
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ing at GWAS data. Analysis of directly assayed rare variants
is challenging statistically because methods developed for
common variants are underpowered. Commercial geno-
typing panels employed by GWAS were designed to cover
most of the common variants but have poor coverage of
rare variants, making the analysis even more challenging.
Now, with the publicly available data from the 1000
Genomes Project being rapidly generated and released,19,20
an attempt to detect rare variants with GWAS data is
worthy and holds promise before study-specific
sequencing data become widely available. We note that,
with GWAS data alone, extremely rare variants (for
example, singletons or study population private variants)
still cannot be evaluated. Our focus is on the analysis of
variants in the frequency range of 0.1%–5%, which have
not been adequately assessed in GWAS but can be better
captured either by haplotyping or with the aid of external
sequencing data by multimarker imputation.21–23
Here we propose two methods to search for the aggre-
gated effect of rare variants with GWAS data. Our
approaches do not rely on the availability of external
sequencing data, but they can incorporate such informa-
tion when available. Moreover, our methods make no
assumption on the direction of association of rare alleles
with disease risk. We applied our methods, along with ex-
isting methods proposed in the sequencing context, to
simulated data sets. Our methods demonstrated better
performance across a wide range of scenarios with an
average power improvement of 8.6% (31.6%) in the
absence (presence) of external sequencing data. We alsoel Hill, NC 27599, USA; 2Department of Biostatistics, University of North
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applied our methods to the Wellcome Trust Case-Control
Consortium (WTCCC) type 1 diabetes (T1D [MIM
222100]) GWAS data set in the IFIH1 (MIM 606951) gene
region, where both common and multiple rare variants
have been found to influence the risk of T1D.2,24,25
Our first test is a weighted haplotype test. Assume
a sample of N diploid individuals is collected, among
whichNcs are affected cases andNct are unaffected controls.
Letm denote the number of genotyped markers in a region
of interest. Further denote haplotypes of the N individuals
byH¼ (H1,H2,.,Hi,.,HN)t, whereHi¼ {Hi,1,Hi,2} are the
two haplotypes carried by the ith individual, consisting of
the m markers in the region. For each individual i, we
define a weighted haplotype score as follows:
WHSi ¼
X2
j¼1
WHi;j ;
in which the sum is taken over the two haplotypes of indi-
vidual i. Wh stands for the weight of haplotype h and is
defined as
Wh ¼ Iðh˛CÞ$ð1ÞIðh˛PÞ$Sh;
in which C is the set of disease-contributing haplotypes
including both risk and protective haplotypes, P is the
set of disease-protective haplotypes (note that P is a subset
of C), and Sh is a score assigned to haplotype h. Following
the weighting scheme proposed by Madsen and Brown-
ing13 for SNPs, we define Sh as
Sh ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Nct$fct;h$

1 fct;h
r
;
in which fct,h denotes the adjusted frequency of haplotype
h among controls and is defined as
fct;h ¼
Cct;hþ1
2ðNct þ 1Þ ;
in which Cct,h is the number of haplotype h among
controls. The rationale of using such a score is that a rare
variant (most likely untyped in GWAS) is more likely to
be tagged by a rare haplotype than by a common haplo-
type, and thus rare haplotypes should receive more weight
in the analysis.
To define the sets of the disease-contributing and
disease-protective haplotypes, we first split the data into
a testing set and a training set and then compared the
haplotype frequencies between cases and controls in the
training set according to the formula below:
8><
>:
h˛C if j f trcs;h  f trct;h j > m
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
f tr
ct;hð1f trct;hÞ
2Ntr
ct
;
r
h˛P if f trcs;h  f trct;h < m
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
f tr
ct;hð1f trct;hÞ
2Ntr
ct
;
r (Equation 1)
with tr standing for the training set. Here, m is a constant
that is determined by a prespecified type I error rate. For
example, m ¼ 1.28 (1.64) corresponds to a type I error ofThe American0.2 (0.1). Following Zhu et al.,14 we set m ¼ 1.28 and
randomly selected 30% of the samples for training in the
analysis.
We note that by explicitly modeling the two sets of
haplotypes as described above, we do not need to make
assumptions about the direction of association between
rare alleles and disease risk. Weighted haplotype scores
are calculated in the testing set after identifying the two
sets of haplotypes with the training set. To assess whether
the rare variants are significantly associated with the
disease, we can perform a standard Wilcoxon26 test on
the weighted haplotype scores and assess the significance
of the test by permutations. For each permuted data set,
the training set and the testing set will be obtained in
a similar fashion as the original data set.
Because typical GWAS data consist of genotypes rather
than haplotypes, we need to infer haplotypes from un-
phased genotypes. This step can be done via standard
phasing methods, including PHASE, fastPHASE, MaCH,
and Beagle.22,27–29 We used MaCH, which allows the
incorporation of external genotyping, haplotyping, or
sequencing data. Our weighted haplotype approach can
be applied to haplotypes consisting of GWAS markers
alone or to haplotypes including additional markers via
incorporation of external reference data.
Our second test is a weighted imputation dosage test.
Following the notations defined above, we assume that
there are a total ofMmarkers genotyped or sequenced after
the incorporation of one or more external data sets (e.g.,
the International HapMap Project30,31 or the 1000
Genomes Project19). We have previously described a
hidden Markov model-based method that imputes un-
typed markers in study samples by exploiting external
data as reference, which was implemented in software
MaCH and has become standard in GWAS analysis.32 Let
D ¼ (D1, D2, ., Di, ., DN)t denote the dosage matrices
across M markers for the N study subjects, in which Di ¼
(Di,1, Di,2, ., Di,j, ., Di,M) denotes the dosages of the i
th
individual. Here Dij is the dosage for the i
th individual at
marker j, which is defined as the expected number of the
rare allele at marker j. Now we define the weighted dosage
score for each individual i as
WDSi ¼
XM
j¼1
Iðj˛MCÞ$ð1ÞIðj˛MPÞ$Di;j;
in which the summation is taken over all M markers withgenotype dosage scores. Here MC is the set of markers
with the rare allele that contributes to disease risk, and
MP is the set of markers with the rare allele that decreases
disease risk. We define these two sets by examining
frequency difference between cases and controls, similar
to Equation 1 for the weighted haplotype test. After obtain-
ing the scores, the standardWilcoxon test is applied to test
for association with the disease, and its significance is as-
sessed via permutation.
We compared our proposed methods with the following
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Table 1. Abbreviation and Description of Tests Applied
Test Abbreviation Description
WDS Weighted dosage test on genotyped plus imputed
SNPs with external sequencing data
WHS Weighted haplotype test on genotyped plus
imputed SNPs with external sequencing data
WHG Weighted haplotype test on genotyped SNPs
only
HG Haplotype grouping test proposed by Zhu et al.14
WSall Original weighted SNP test aggregating evidence
over all (regardless of MAF) SNPs proposed by
Madsen and Browning13
WSrare Modified weighted SNP test aggregating evidence
over rare (MAF < 5%) SNPs only
RVC Rare variant collapsing method proposed by Li
and Leal12(1) Weighted SNP Test (denoted by WS)13 is a weighted-
sum method in which rare alleles are aggregated and
weighted according to a function of minor allele frequency
among controls. Despite the fact that the method was
proposed as a test for ‘‘rare mutations,’’ it indeed sums
over all markers by giving smaller weight to alleles with
higher frequency. Although an omnibus regional-based
test that evaluates both common and rare variants is some-
times desired, here we are interested in a regional-based
test for rare variants only, assuming that common variants
have been thoroughly evaluated by large-scale GWAS.
Because of this, we compared our methods with both the
originally proposed test (denoted by WSall) and a modified
version of it (denoted by WSrare), in which only markers
with minor allele frequency (MAF) < 5% are included. (2)
Zhu and colleagues proposed a haplotype grouping
method (denoted by HG)14 that counts the number of
rare risky haplotypes for each individual and uses a Fisher’s
exact test for testing. (3) We also applied the rare variant
collapsing method (denoted by RVC) proposed by Li and
Leal,12 which groups each individual into one of two
groups: carrying any rare allele or not. Together with
case-control status, a 2 3 2 table is generated, and a stan-
dard test for contingency table (e.g., chi-square test for
independence) is applied. Table 1 lists the above-described
tests and their abbreviations.
We simulated 10,000 chromosomes for a series of 100
1 Mb regions with a coalescent model that mimics linkage
disequilibrium (LD) in real data, accounts for variations in
local recombination rates, and models population history,
consistent with the HapMap CEU (CEPH people from
Utah, USA) samples.33 We then took a random subset of
1000 simulated chromosomes (i.e., 500 individuals) to
serve as the external reference, mimicking the targeting
sample size for the 1000 Genomes Project. To generate
a set of GWAS markers in each region, we first randomly
picked 120 chromosomes, mimicking Phase II HapMap
CEU data. We then ascertained and thinned polymorphic
sites to match marker density and allele frequency spec-
trum of their real-data counterparts. Based on LDmeasures
calculated with the 120 chromosomes, we selected a set of
100 SNPs for each region that included 90 tagSNPs tagging
the largest number of SNPs and 10 additional SNPs picked
at random among the remaining SNPs. The final set of re-
tained SNPs (GWAS markers in the region) captured ~78%
of the common variants (MAF > 5%) at a conventional r2
cutoff of 0.8, similar to the real-data performance of the
Illumina HumanHap300 BeadChip SNP genotyping
platform.
Within each simulated 1Mb region, we picked an ~50 kb
region as the causal region in which we assume only rare
variants (variants with population MAF between 0.1%
and 5%) contribute to the disease risk. We randomly
selected d% of the rare variants in the causal region to be
causal, i.e., to influence disease risk. Among these rare vari-
ants, we further assume that r% of them increase disease
risk, whereas the remaining (100 – r)% decrease disease730 The American Journal of Human Genetics 87, 728–735, Novembrisk. To ensure that each variant only has a small contribu-
tion to the overall disease risk, we followed a model similar
to that proposed by Madsen and Browning.13 Specifically,
the contribution of each causal variant j to the overall
genotype relative risk (GRR) is defined as
GRRj ¼

PAR
ð1 PARÞ$MAFj þ 1
ð1ÞIðxj¼1Þ
;
in which PAR is the population attributable risk and xj ¼ 1
indicates that the rare allele of marker j decreases disease
risk. Following Madsen and Browning,13 we used the
same marginal PAR for each causal variant, which intrinsi-
cally assumes that alleles with lower frequency have higher
GRR than alleles with higher frequency. In our 50 kb core
region, there are ~500 SNPs with MAF < 5%; the distribu-
tions of MAFs and GRRs (without loss of generality,
assuming all rare alleles increase disease risk) are shown
in Figure S1 available online.
To generate the chromosomes for an individual, we
randomly selected two chromosomes {H1, H2} from the re-
maining 9000 chromosomes that were not selected as
external reference. The disease status of the individual
was assigned according to
Pðaffected j fH1;H2gÞ ¼ f03
Y2
k¼1
Ymc
j¼1
GRR
IðHk;j¼ajÞ
j ;
in which f0 is the baseline penetrance and was fixed at 10%
in our simulations (1% and 5% were also evaluated and re-
sulted in similar patterns but with slight power loss), mc is
the number of causal SNPs, and aj is the rare allele of SNP j.
Sampling was repeated until the desired number of cases
and controls was reached. In our simulations, d took values
from 10% to 50% by an increment of 10%. Among the
disease risk influencing loci, we set the value of r, the
percentage of rare alleles increasing disease risk, at 5%,
20%, 50%, 80%, and 100%, respectively.er 12, 2010
Figure 1. Comparison of Power by r, Percent of Rare Alleles in
the Causal Region that Increase Disease Risk
Power of all tests was assessed at the 5% level by using empirical
significance threshold determined by 1000 null data sets per
region. 50% of the rare alleles in the causal region were assumed
to contribute to disease risk (i.e., d fixed at 50%), and the PAR of
each contributing SNP was fixed at 0.5%.For each of the 100 regions, two independent data sets
with 1000 cases and 1000 controls were simulated with
the model described above. In addition, five independent
null data sets of the same sample size were simulated,
assuming no genetic effect by randomly sampling 4000
chromosomes (i.e., 2000 individuals) from the pool of
9000 chromosomes. Average power was estimated based
on the 100 regions, which represent a wide range of LD
patterns. To account for local LD differences, we permuted
each of the null sets 200 times to obtain region-specific
empirical significant threshold. For the weighted haplo-
type analysis, we considered two versions: WHG, which
uses haplotypes consisting of GWAS SNPs only, and
WHS, which uses haplotypes encompassing both geno-
typed and imputed SNPs. For both the weighted haplotype
tests and the weighted dosage test, untyped SNPs with Rsq
(estimated imputation quality) < 0.3 were discarded from
subsequent analysis.22 In all analyses, we used haplotypes
reconstructed from the unphased genotypes and imputed
genotypes for markers that are not included on the
GWAS chip. Our methods (WHG, WHS, and WDS),
together with WSall, WSrare, HG, and RVC, were applied
to the 1000 null data sets within each region to determine
the region-specific empirical significance threshold,
ensuring the correct type I error rate of 0.05 for all tests.
Figure 1 shows the empirical power of our methods rela-
tive to the other four methods proposed in the sequencing
context as a function of r, the proportion of rare alleles
increasing disease risk, which ranges from 5% to 100%.
We fixed PAR at 0.5% and d (percent of disease-influencingThe Americanrare variants) at 50%. Although the synergy assumption is
more reasonable for rarer alleles than for common alleles
because rarer alleles tend to disrupt gene function, our
knowledge regarding the direction of rarer alleles is still
limited. Therefore, methods robust to such an assumption
are desirable. Although all methods have decreased power
when rare alleles work in different directions, our methods
performed better by explicitly modeling the direction of
association. For example, compared with the haplotype
grouping (HG) method, the advantage of our weighted
haplotype method (WHG, on GWAS SNPs only without
the aid of external sequencing data) manifests more
when a larger proportion of the rare alleles is protective:
power gain is 9.1% when all of the rare alleles at disease-
contributing loci increase disease risk, and the power
gain increases to 20.7% when only 5% of the rare alleles
increase disease risk.
Our proposed tests increase power through two different
mechanisms: by using haplotypes to better capture infor-
mation for rare variants (mostly untyped in GWAS) and
by using external sequencing data to impute rare variants.
Let us consider the first mechanism by examining tests on
GWAS data alone, namely WHG, HG, WSall, WSrare, and
RVC. At GWAS level, haplotype-based methods clearly
manifest their advantages. Among the five methods, the
two haplotype-based methods (WHG and HG) rank as
the best two across the five scenarios presented in Figure 1.
Note thatWSall andWSrare can be viewed as special cases of
WDS, where the dosages only take values 0, 1, or 2 at
directly genotyped markers. Therefore, at the GWAS level,
haplotype-based methods are preferred over single-marker
dosage-based tests. This is because causal rare variants are
better captured by haplotypes constructed from GWAS
SNPs than by those SNPs themselves. Between the two
haplotype-based methods, our weighted haplotype
method (WHG) increases power by an average of 13.2%
over HG by weighting individual haplotypes (instead of
lumping them together into groups) and by explicitly
modeling the direction of association.
Next we consider the second mechanism by looking at
tests that incorporate external sequencing data, namely
WHS and WDS. Both are more powerful than WHG, the
best test based on GWAS data alone. The average power
gain of WHS and WDS over WHG is 3.8% and 22.0%,
respectively. At this pseudosequencing level (i.e., study
subjects imputed with SNPs of sequencing density),
a single-marker dosage-based test is more powerful than
haplotype-based methods. This is not surprising because,
at the pseudosequencing level, causal rare variants are
better captured by their imputed counterpart than by
haplotypes. The same applies to data at the sequencing
level (i.e., when study subjects are directly sequenced).
Of course, if there are genuine haplotype effects, we antic-
ipate that WHS will perform better. To quantify the extent
of better performance, we need more empirical data on the
distribution of genuine haplotype effects, which is beyond
the scope of this paper. Currently, we have little evidenceJournal of Human Genetics 87, 728–735, November 12, 2010 731
Figure 2. Comparison of Power by PAR
Power of all tests was assessed at the 5% level by using empirical
significance threshold determined by 1000 null data sets per
region. 50% of the rare alleles in the causal region were assumed
to contribute to disease risk (i.e., d fixed at 50%), and all contrib-
uting rare alleles were assumed to increase disease risk (i.e., r fixed
at 100%).
Figure 3. Comparison of Power by d, Percent of Disease-
Contributing Rare Variants
Power of all tests was assessed at the 5% level by using empirical
significance threshold determined by 1000 null data sets per
region. All rare alleles in the causal region were assumed to
increase disease risk (i.e., r fixed at 100%), and the PAR of each
contributing SNP was fixed at 0.5%.even to convincingly conclude the presence of genuine
haplotype effects. Therefore, with the presence of external
sequencing data and under the assumption that single
variants cumulatively contribute to disease risk, we recom-
mend WDS over WHS.
Figure 2 and Figure 3 show the power of different tests
under situations with varying PAR and varying percentage
of disease-contributing rare variants. We fixed the value of
d (percentage of rare alleles influencing disease risk) at
100%. The value of r (percent of causal alleles increasing
disease risk) was fixed at 50% for Figure 2, and the per
SNP PAR was fixed at 0.5% for Figure 3. Although the
power decreases with decreasing PAR or decreasing
percentage of disease-contributing variants for all
methods, our WHG and WHS are comparable, if not
slightly better, than other alternatives, and our WDS is
more powerful than the other methods by utilizing
sequencing information from external data and explicitly
modeling the SNP-level dosages.
We note that tests on rare GWAS SNPs only (WSrare and
RVC) are less powerful in general, because at GWASmarker
density, a typical gene region may contain few, if any,
directly genotyped rare variants. In our simulations, 64
out of the 100 regions have no rare variants within the
~50 kb core causal regions. These tests, proposed in the
sequencing context, are thus not suitable for analyzing
GWAS data.
Encouraged by results from simulations, we applied our
methods to real data. Multiple common and rare variants
in IFIH1, a cytoplasmic helicase that mediates induction732 The American Journal of Human Genetics 87, 728–735, Novembof interferon response to viral RNA, have been established
to influence risk of T1D. In particular, variants disrupting
IFIH1 function have been suggested to confer protection
from T1D.2 We took the WTCCC T1D data to search for
rare variants associated with T1D susceptibility. In the
WTCCC GWAS data set, 10 SNPs were found in the IFIH1
region, with four being monomorphic in both the T1D
set and the two control sets (NBS and 58C), leaving six
SNPs for analysis. These six SNPs and their allele frequen-
cies among cases and controls are tabulated in Table 2.
We applied our methods, along with the others, to this
data set. Because the common SNP rs1990760 (MAF >
30%) in IFIH1 has been found to influence T1D risk,24,25
we restricted our analysis to SNPs or haplotypes with
frequency < 5% to rule out signals due to LD with
rs1990760. Our goal is to assess whether there is any
residual association with T1D because of rare variants,
which have been ignored in the previous GWAS analysis.
We used the March 2010 release of 60 CEU individuals
from the 1000 Genomes Project as reference for imputa-
tion. We used SNPs in the ~50 kb IFIH1 gene region plus
2 Mb flanking on each side for phasing and imputation.
Again, we discarded imputed SNPs with Rsq < 0.3. For
the haplotype grouping method, the original test failed
in this data set because rare alleles in IFIH1 are associated
with decreased risk of T1D. P values based on 100,000
permutations are shown in Table 3. The p values from
our methods are in the order of 103, whereas the most
significant p value from existing methods is >0.17. This
example clearly demonstrates the importance of usinger 12, 2010
Table 2. Allele Frequencies of the Six Polymorphic SNPs in IFIH1
SNP 58C NBS T1D
rs3747517 27.66% 26.31% 24.16%
rs41463049 1.12% 1.06% 1.02%
rs6432714 1.18% 1.06% 1.02%
rs13023380 48.88% 47.46% 45.24%
rs7559103 0.17% 0.10% 0.00%
rs12479125 1.18% 1.06% 1.02%
Table 3. Permutation p Values, Based on 100,000 Permutations,
for the Association of Rare Variants in IFIH1 with T1D Risk in
WTCCC Data Set
Test p Value
WDS 0.00431
WHS 0.00738
WHG 0.00746
HG 1.000
WSrare 0.329
RVC 0.179appropriate methods when searching for the effect of rare
variants with GWAS data.
In summary, we have proposed two tests to assess the
impact of multiple rare variants on disease risk. We show
through simulations and a real-data example that by maxi-
mally extracting information from GWAS data, as well as
the incorporation of publicly available sequencing data,
ourmethods provide an intermediate solution for the anal-
ysis of rare variants before study-specific sequencing data
become available. Our results suggest that at the GWAS
level, haplotype-based methods are more powerful, but at
the pseudosequencing level (i.e., GWAS data imputed
with publicly available sequencing data), a test based on
weighted sum of single-marker dosages is more powerful.
By assuming that we know the 50 kb causal region a pri-
ori, we may have overestimated the power in the simula-
tions. We thus repeated the experiment by extending the
test region to 100 kb (25 kb flanking region on either
side of the core region) and to 200 kb (75 kb flanking on
either side) to mimic the lack of knowledge on the lengths
of regulatory regions flanking a gene or an exon. We found
that the power difference is within 2%. In most situations,
power was slightly lower, but in a few situations, power
was slightly higher, because some variants in the
noncausal flanking region happen to tag the causal vari-
ants better because of LD. These results are not surprising,
because our methods can eliminate irrelevant SNPs or
haplotypes by comparing frequency differences between
cases and controls in the training data set.
The analysis of rare variants with GWAS data is chal-
lenging because of several reasons. First, SNPs picked by
the commonly used GWAS genotyping platforms have
poor coverage for rare variants in general. Second, we
have no catalog of rare variants in our genome, and our
knowledge regarding their impact on phenotypic varia-
tions is still limited. Third, traditional association tests
are suitable for the analysis of common variants but are
generally underpowered for the analysis of rare variants.
By utilizing LD information and incorporating publicly
available sequencing data, we show that hunting for rare
variants with GWAS data is possible.
Ourmethods are proposed for GWAS data, which are still
the most commonly available type of data for gene
mapping studies. In both our simulations and the realThe Americandata analysis of T1D with gene IFIH1, we only have
GWAS data on the study subjects. We compared our
methods with alternatives proposed for sequencing data
and demonstrated that methods that are specifically tar-
geted for the analysis of rare variants in GWAS settings
such as ours perform much better than methods that are
developed for sequencing data. We note that our targeted
‘‘rare’’ variants (MAF 0.1%–5%) differ from those in
methods developed in the sequencing context (including
extremely rare variants with MAF < 0.5% or 0.1%). For
extremely rare variants (MAF < 0.5%), our methods are ex-
pected to have low power because of low phasing and
imputation quality with GWAS data. Although our
methods are proposed for GWAS data, they can be applied
directly to sequence data or to partially sequenced data in
which selected individuals under study are sequenced.
Therefore, our methods provide a useful alternative but
are not meant to replace existing methods, given funda-
mental differences in their targeted data type (GWAS
versus sequencing) and targeted MAF range. Because the
performance of our weighted imputation dosage test
depends critically on the imputation quality of rare vari-
ants (MAF < 5%), we decided to evaluate the quality in
real data from the FUSION project34 by masking and
imputing all rare variants in a subset of individuals with
constructed haplotypes encompassing both common and
rare variants from an independent set of FUSION individ-
uals (of varying sizes) as reference. We found that imputa-
tion quality for rare variants improves when the sample
size in the reference panel increases. For example, the accu-
racy among the heterozygotes (r2) increases from 83.4%
(74.3%) to 97.0% (92.9%) when the number of reference
haplotypes increases from 60 to 1000 (Figure S2).
Our methods and others evaluated in this study were
developed for the analysis of rare variants, but we have
found that inclusion of common variants can increase
the power (data not shown). This is demonstrated by the
superior performance of WSall (test that includes all vari-
ants) over WSrare (test that only includes rare variants),
even though only rare variants that contribute to disease
risk were included in our simulations. This is not entirely
surprising, because common variants or haplotypes can
carry some information of untyped rare variants. OneJournal of Human Genetics 87, 728–735, November 12, 2010 733
major issue of including common variants in testing is
misclassification, that is, inclusion of variants that do not
contribute to disease risk. However, by searching for
frequency difference in a training set, our methods can
alleviate this misclassification issue. In general, we recom-
mend testing common variants first, for instance, via stan-
dard single-marker test. If there is no evidence of associa-
tion with common variants, we then search the entire
MAF space for the effect of rare variants. When common
variants are found to be associated (such as in the IFIH1
example), we should restrict our attention to rare variants
or haplotypes only to alleviate the residual effects of
common variants.
Both of our tests assess the effect of multiple variants in
aggregate in a predefined genomic region, typically
a known gene annotated by RefSeq or other gene annota-
tions. For real-life GWAS data, we recommend performing
the tests for all known genes if no prior knowledge exists or
for a list of one or more candidate genes in the presence of
such knowledge. We note that the weighted dosage-based
test is more flexible than the haplotype-based test in that it
can be used to test for an arbitrary set of SNPs (for example,
nonsynonymous rare SNPs in a pathway), which may
involve SNPs on different chromosomes.
One issue with the haplotype-based test is that the
haplotypes are not known but instead are inferred with
uncertainty. Fortunately, most phasing methods,
including PHASE andMaCH, can estimate the probabilities
of possible haplotype configurations for each individual in
addition to providing the best-guess haplotypes. With
these estimates, we can easily model the phasing uncer-
tainty into our weighted haplotype test by allowing
possible haplotype configurations of each individual to
contribute to the haplotype frequency estimates, as well
as to the weighted haplotype score, according to their esti-
mated probabilities. An alternative approach is to perform
multiple imputation on 5–10 imputed data sets.35 Note
that each imputed data set has to be drawn from a different
posterior distribution to ensure proper multiple imputa-
tion. This can be achieved either by imputing from
different reference sets (for example, from bootstrap
samples of the HapMap or 1000 Genomes reference set)
or by drawing from different iteration in a full Bayesian
framework in which the model parameters are also up-
dated in each iteration. Neither approach had noticeable
impact on the IFIH1 real data set, but further work is war-
ranted.
Both of our proposed tests can be extended to analyze
quantitative traits and to accommodate covariates. Both
of our tests, in a nutshell, derive one ‘‘genetic score’’ for
each individual and assess the association between the
genetic score and phenotype of interest. The genetic score
is a weighted sum of contributing SNP dosages or haplo-
types. Although the weights are defined for dichotomous
trait in this work, we can easily extend the work to quanti-
tative traits by first estimating the weights, for the very
simple example, via regression, then deriving the genetic734 The American Journal of Human Genetics 87, 728–735, Novembscore accordingly, and finally performing the association
testing. In the above general setting, covariates can be
conveniently incorporated.Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
We thank Mike Boehnke, Karen Mohlke, Laura Scott, and Ethan
Lange for helpful discussions. We also thank the FUSION and
WTCCC research teams for providing their GWAS data. Y.L. is
partially supported by DK078150 and CA082659. M.L. is sup-
ported by R01HG004517 and R01HG005854.
Received: August 17, 2010
Revised: October 12, 2010
Accepted: October 14, 2010
Published online: November 4, 2010Web Resources
The URLs for data presented herein are as follows:
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